Business

Teva, Celltrion Maintain Slender Discount to Rituxan

May 4th 2020

By Tony Hagen

Although Pfizer has offered a more attractive discount for its rituximab biosimilar, Teva Pharmaceutical Industries and Celltrion Healthcare have decided not to match that discount for their own rituximab biosimilar, which is more costly.

Amgen Sees Biosimilar "Give and Take"

May 2nd 2020

By The Center for Biosimilars

Amgen saw biosimilar competition eat a larger share of its innovator drug revenue but also earned some biosimilar pocket money of its own.

Sanofi Insulin Biosimilar Gets CHMP Nod

May 1st 2020

By The Center for Biosimilars

The Committee for Medicinal Products for Human Use (CHMP) has given its recommendation for the marketing authorization of Insulin aspart Sanofi.

The Top 5 Biosimilars Articles for the Week of April 27

May 1st 2020

Here are the top 5 biosimilars articles for the week of April 27, 2020.

Amgen Claims Infringement of a Patent That Didn't Exist

May 1st 2020

By Tony Hagen

Trying to carve back its market share for Neupogen, its filgrastim originator product, Amgen is hoping product exclusivity can be backdated.

Pfizer Says Biosimilar Competition Cuts Both Ways

April 30th 2020

By Tony Hagen

Pfizer is battling biosimilar competition as its brands lose exclusivity but it is fighting fire with fire, launching multiple biosimilars of its own. Biogen has extended its commercialization agreements for biosimilars and said its earnings picture improved in the first quarter of 2020.

In Europe, Secondary Patents Can't Stop Biosimilars, Study Says

April 29th 2020

By Deana Ferreri, PhD

European investigators say their analysis of court cases involving innovator monoclonal antibodies suggests secondary patents have generally failed to stop biosimilar competition.

Novartis Reports 31% Growth in Biosimilar Division

April 28th 2020

By The Center for Biosimilars

With a growing portfolio of biosimilars, Novartis saw a 31% increase in biopharmaceutical sales for the first quarter of 2020, despite the pandemic.

Genentech's Misfire on Kanjinti Creates Opening

April 28th 2020

By Tony Hagen

Taking an abundance of time to file a motion to block Kanjinti from coming to market, Genentech unwittingly may have tipped the scales in favor of biosimilar applicants.

Henlius Manufacturing Plant Gains European Stamp of Approval

April 27th 2020

By Tony Hagen

Henlius Biotech said its manufacturing facility has met European standards for production of its trastuzumab biosimilar candidate, which the company said is "a passport" for potential commericialization across the globe.